SCHEMBL991970

SCHEMBL991970

CCc1cc(Cl)[nH]n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240846 0.73 — —
SCHEMBL15017181 0.73 — —
SCHEMBL1205841 0.73 — —
SCHEMBL19560131 0.73 — —
SCHEMBL1072255 0.71 — —
SCHEMBL1629567 0.71 — —
SCHEMBL28912275 0.70 — —
SCHEMBL21323397 0.68 HCAR2 (0.52) —
SCHEMBL4916584 0.68 — —
SCHEMBL1204783 0.68 HCAR2 (0.46) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024262911-A1 NOVEL PYRAZOLO PYRIMIDINE-BASED COMPOUND AND USE THEREOF 주식회사 에이조스바이오 2024-12-26 — — WO disclosed
EP-3706749-B1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF ANGEX PHARMACEUTICAL INC (US) 2024-03-13 — — EP disclosed
CN-111971287-B Macrocyclic compounds as TRK kinase inhibitors 重庆复尚源创医药技术有限公司 2023-06-02 — — CN disclosed
CN-115551863-A Salt form, crystal form, pharmaceutical composition and application of tyrosine kinase inhibitor 贝达药业股份有限公司 2022-12-30 — — CN disclosed
EP-3891152-A1 TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF Betta Pharmaceuticals Co., Ltd (CN) 2021-10-13 — — EP disclosed
WO-2021047584-A1 SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2021-03-18 — — WO disclosed
EP-3774812-A1 MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS Fochon Pharmaceuticals, Ltd. (CN) 2021-02-17 — — EP disclosed
EP-3765462-A1 SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-A] PYRIMIDINE AND IMIDAZO [1, 2-B] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS Fochon Pharmaceuticals, Ltd. (CN) 2021-01-20 — — EP disclosed
US-20200385386-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF ANGEX PHARMACEUTICAL, INC. 2020-12-10 — — US disclosed
CN-111971287-A Macrocyclic compounds as TRK kinase inhibitors 重庆复创医药研究有限公司 2020-11-20 — — CN disclosed
EP-3706749-A1 MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF Angex Pharmaceutical, Inc. (US) 2020-09-16 — — EP disclosed
WO-2020114499-A1 TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF BETTA PHARMACEUTICALS CO., LTD (CN) 2020-06-11 — — WO disclosed
WO-2019184955-A1 MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2019-10-03 — — WO disclosed
WO-2019174598-A1 SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS FOCHON PHARMACEUTICALS, LTD. (CN) 2019-09-19 — — WO disclosed
EP-2967073-B9 LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2019-04-10 — — EP disclosed
EP-3268367-A1 CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY Merck Sharp & Dohme Corp. (US) 2018-01-17 — — EP disclosed
WO-2016144844-A1 CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY MERCK SHARP & DOHME CORP. (US) 2016-09-15 — — WO disclosed
EP-2451812-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS Array Biopharma, Inc. (US) 2012-05-16 — — EP disclosed
WO-2011006074-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-01-13 — — WO disclosed
WO-2008013622-A2 FUNGICIDAL AZOCYCLIC AMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-01-31 — — WO disclosed
Send feedback